Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $33.17B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: DXCM stock price vs BMRN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Needs BMRN P/E.
Implied fair value · at DXCM's multiple
Needs DXCM P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DXCM FY 2025 (ended Dec 31, 2025) · BMRN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 91% equity / 9% debt · EV / Revenue 7.63x · EV / EBITDA 26.75x
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
DXCM carries the larger enterprise value at $35.57B against $12.07B; BMRN trades on the lower EV / Revenue multiple (3.75x vs 7.63x); BMRN on the lower EV / EBITDA (21.37x vs 26.75x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DEXCOM, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.21x
0.08x
Net debt / EBITDA
Leverage against operating earnings
1.81x
-1.43x
Cash and equivalents
Liquid reserves on the balance sheet
$917.70M
$1.31B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
DXCM vs ABT
Medtronic plc
DXCM vs MDT
BECTON DICKINSON & CO
DXCM vs BDX
VERTEX PHARMACEUTICALS INC / MA
DXCM vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
DXCM vs ALNY
Sarepta Therapeutics, Inc.
DXCM vs SRPT
REGENXBIO Inc.
DXCM vs RGNX
IONIS PHARMACEUTICALS INC
DXCM vs IONS
PTC THERAPEUTICS, INC.
DXCM vs PTCT
$3.32B
$505.32M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
